NO326206B1 - Farmasoytisk tablett med kontrollert frigivelse av alfuzosinhydroklorid - Google Patents

Farmasoytisk tablett med kontrollert frigivelse av alfuzosinhydroklorid Download PDF

Info

Publication number: NO326206B1
Authority: NO; Norway
Prior art keywords: layer; tablet; layers; stated; alfuzosin hydrochloride
Prior art date: 1996-08-29

Application number

NO19990944A

Other languages

English (en)

Norwegian (no)

Other versions

NO990944L (no

NO990944D0 (no

Inventor

Alain Dufour

Ubaldo Conte

Lauretta Maggi

Pascal Grenier

Guy Vergnault

Francois Xavier Jarreau

Clemence Rauch-Desanti

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-29

Filing date

1999-02-26

Publication date

2008-10-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26232935&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO326206(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-08-29 Priority claimed from FR9610551A external-priority patent/FR2752737B1/fr

1999-02-26 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

1999-02-26 Publication of NO990944D0 publication Critical patent/NO990944D0/no

1999-04-27 Publication of NO990944L publication Critical patent/NO990944L/no

2008-10-20 Publication of NO326206B1 publication Critical patent/NO326206B1/no

Links

229960003103 alfuzosin hydrochloride Drugs 0.000 title claims description 54
YTNKWDJILNVLGX-UHFFFAOYSA-N alfuzosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 YTNKWDJILNVLGX-UHFFFAOYSA-N 0.000 title claims description 54
238000013270 controlled release Methods 0.000 title claims description 9
239000008187 granular material Substances 0.000 claims description 99
239000000203 mixture Substances 0.000 claims description 38
239000013543 active substance Substances 0.000 claims description 37
239000000126 substance Substances 0.000 claims description 22
230000004888 barrier function Effects 0.000 claims description 21
230000006835 compression Effects 0.000 claims description 15
238000007906 compression Methods 0.000 claims description 15
210000001035 gastrointestinal tract Anatomy 0.000 claims description 12
230000008961 swelling Effects 0.000 claims description 12
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 10
229920001477 hydrophilic polymer Polymers 0.000 claims description 10
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
239000000546 pharmaceutical excipient Substances 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
239000012530 fluid Substances 0.000 claims description 6
239000011248 coating agent Substances 0.000 claims description 5
238000000576 coating method Methods 0.000 claims description 5
229940075507 glyceryl monostearate Drugs 0.000 claims description 5
239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 5
230000035515 penetration Effects 0.000 claims description 5
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
229930195725 Mannitol Natural products 0.000 claims description 4
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
229920002472 Starch Polymers 0.000 claims description 4
239000013060 biological fluid Substances 0.000 claims description 4
229920001577 copolymer Polymers 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
239000008101 lactose Substances 0.000 claims description 4
239000000594 mannitol Substances 0.000 claims description 4
235000010355 mannitol Nutrition 0.000 claims description 4
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
239000008108 microcrystalline cellulose Substances 0.000 claims description 4
229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
235000019698 starch Nutrition 0.000 claims description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
239000001856 Ethyl cellulose Substances 0.000 claims description 3
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
235000010980 cellulose Nutrition 0.000 claims description 3
229920002678 cellulose Polymers 0.000 claims description 3
239000001913 cellulose Substances 0.000 claims description 3
-1 cetomacrogol Chemical compound 0.000 claims description 3
235000019325 ethyl cellulose Nutrition 0.000 claims description 3
229920001249 ethyl cellulose Polymers 0.000 claims description 3
125000005456 glyceride group Chemical class 0.000 claims description 3
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 2
229920000856 Amylose Polymers 0.000 claims description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
229920001661 Chitosan Polymers 0.000 claims description 2
229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
229920000926 Galactomannan Polymers 0.000 claims description 2
229920001503 Glucan Polymers 0.000 claims description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
229920000057 Mannan Polymers 0.000 claims description 2
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
229920002732 Polyanhydride Polymers 0.000 claims description 2
229920002305 Schizophyllan Polymers 0.000 claims description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
229920002125 Sokalan® Polymers 0.000 claims description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
150000001252 acrylic acid derivatives Chemical class 0.000 claims description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
235000010443 alginic acid Nutrition 0.000 claims description 2
239000000783 alginic acid Substances 0.000 claims description 2
229920000615 alginic acid Polymers 0.000 claims description 2
229960001126 alginic acid Drugs 0.000 claims description 2
150000004781 alginic acids Chemical class 0.000 claims description 2
239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
229920001525 carrageenan Polymers 0.000 claims description 2
235000010418 carrageenan Nutrition 0.000 claims description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 2
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 2
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 claims description 2
235000010944 ethyl methyl cellulose Nutrition 0.000 claims description 2
239000001761 ethyl methyl cellulose Substances 0.000 claims description 2
230000002209 hydrophobic effect Effects 0.000 claims description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
239000000787 lecithin Substances 0.000 claims description 2
235000010445 lecithin Nutrition 0.000 claims description 2
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 2
LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 claims description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 2
229920000609 methyl cellulose Polymers 0.000 claims description 2
XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 claims description 2
150000002942 palmitic acid derivatives Chemical class 0.000 claims description 2
239000001814 pectin Substances 0.000 claims description 2
229920001277 pectin Polymers 0.000 claims description 2
235000010987 pectin Nutrition 0.000 claims description 2
239000008180 pharmaceutical surfactant Substances 0.000 claims description 2
229960000502 poloxamer Drugs 0.000 claims description 2
229920001983 poloxamer Polymers 0.000 claims description 2
229920001308 poly(aminoacid) Polymers 0.000 claims description 2
229920000642 polymer Polymers 0.000 claims description 2
229920000136 polysorbate Polymers 0.000 claims description 2
229940068965 polysorbates Drugs 0.000 claims description 2
229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
IJRHDFLHUATAOS-DPMBMXLASA-M sodium ricinoleate Chemical compound [Na+].CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O IJRHDFLHUATAOS-DPMBMXLASA-M 0.000 claims description 2
229960000776 sodium tetradecyl sulfate Drugs 0.000 claims description 2
UPUIQOIQVMNQAP-UHFFFAOYSA-M sodium;tetradecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOS([O-])(=O)=O UPUIQOIQVMNQAP-UHFFFAOYSA-M 0.000 claims description 2
229940035044 sorbitan monolaurate Drugs 0.000 claims description 2
239000000600 sorbitol Substances 0.000 claims description 2
229960002920 sorbitol Drugs 0.000 claims description 2
235000010356 sorbitol Nutrition 0.000 claims description 2
239000008107 starch Substances 0.000 claims description 2
239000004094 surface-active agent Substances 0.000 claims description 2
229920001285 xanthan gum Polymers 0.000 claims description 2
239000000811 xylitol Substances 0.000 claims description 2
229960002675 xylitol Drugs 0.000 claims description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
235000010447 xylitol Nutrition 0.000 claims description 2
239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
239000010410 layer Substances 0.000 description 172
238000004519 manufacturing process Methods 0.000 description 82
238000000034 method Methods 0.000 description 22
230000008569 process Effects 0.000 description 20
239000000825 pharmaceutical preparation Substances 0.000 description 16
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
239000000843 powder Substances 0.000 description 13
238000012360 testing method Methods 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
239000008119 colloidal silica Substances 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
238000007922 dissolution test Methods 0.000 description 6
238000002156 mixing Methods 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
210000004051 gastric juice Anatomy 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
239000004359 castor oil Substances 0.000 description 4
235000019438 castor oil Nutrition 0.000 description 4
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
239000000243 solution Substances 0.000 description 4
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
229940049654 glyceryl behenate Drugs 0.000 description 3
239000008213 purified water Substances 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
238000009736 wetting Methods 0.000 description 3
239000012738 dissolution medium Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
239000012729 immediate-release (IR) formulation Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229940127554 medical product Drugs 0.000 description 2
229940126601 medicinal product Drugs 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
230000032258 transport Effects 0.000 description 2
206010020880 Hypertrophy Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229960004607 alfuzosin Drugs 0.000 description 1
WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000005056 compaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
238000013265 extended release Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19990944A 1996-08-29 1999-02-26 Farmasoytisk tablett med kontrollert frigivelse av alfuzosinhydroklorid NO326206B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR9610551A FR2752737B1 (fr)	1996-08-29	1996-08-29	Comprime a liberation controlee de chlorhydrate d'alfuzosine
FR9704386		1997-04-10
PCT/FR1997/001515 WO1998008515A1 (fr)	1996-08-29	1997-08-22	Comprime a liberation controlee de chlorhydrate d'alfuzosine

Publications (3)

Publication Number	Publication Date
NO990944D0 NO990944D0 (no)	1999-02-26
NO990944L NO990944L (no)	1999-04-27
NO326206B1 true NO326206B1 (no)	2008-10-20

Family

ID=26232935

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19990944A NO326206B1 (no)	1996-08-29	1999-02-26	Farmasoytisk tablett med kontrollert frigivelse av alfuzosinhydroklorid

Country Status (37)

Country	Link
US (1)	US6149940A (cs)
EP (1)	EP0938318B1 (cs)
JP (1)	JP3797388B2 (cs)
KR (1)	KR100364328B1 (cs)
CN (2)	CN100335057C (cs)
AP (1)	AP1107A (cs)
AR (1)	AR009312A1 (cs)
AT (1)	ATE200864T1 (cs)
AU (1)	AU724490B2 (cs)
BG (1)	BG63768B1 (cs)
BR (1)	BR9713237B1 (cs)
CA (1)	CA2264250C (cs)
CO (1)	CO4920217A1 (cs)
CY (1)	CY2284B1 (cs)
CZ (1)	CZ295066B6 (cs)
DE (1)	DE69704712T2 (cs)
DK (1)	DK0938318T3 (cs)
EE (1)	EE03855B1 (cs)
ES (1)	ES2159400T3 (cs)
GR (1)	GR3036291T3 (cs)
HK (1)	HK1020875A1 (cs)
HU (1)	HU228007B1 (cs)
IL (1)	IL128146A (cs)
IS (1)	IS2091B (cs)
MX (1)	MXPA99001958A (cs)
NO (1)	NO326206B1 (cs)
NZ (1)	NZ334018A (cs)
OA (1)	OA10983A (cs)
PL (1)	PL191546B1 (cs)
PT (1)	PT938318E (cs)
RU (1)	RU2183459C2 (cs)
SI (1)	SI0938318T1 (cs)
SK (1)	SK284388B6 (cs)
TR (1)	TR199900289T2 (cs)
TW (1)	TW522023B (cs)
UA (1)	UA69374C2 (cs)
WO (1)	WO1998008515A1 (cs)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6720471B1 (en)	1998-04-28	2004-04-13	The Procter & Gamble Company	Absorbent articles having reduced rewet with distribution materials positioned underneath storage material
US7022683B1 (en)	1998-05-13	2006-04-04	Carrington Laboratories, Inc.	Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
FR2784583B1 (fr) *	1998-10-16	2002-01-25	Synthelabo	Composition pharmaceutique a residence gastrique et a liberation controlee
ES2270982T3 (es)	2000-02-04	2007-04-16	Depomed, Inc.	Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
AR030557A1 (es) *	2000-04-14	2003-08-27	Jagotec Ag	Una tableta en multicapa de liberacion controlada y metodo de tratamiento
FR2820318B1 (fr) *	2001-02-08	2005-12-23	Ellipse Pharmaceuticals	Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu
FR2820319B3 (fr) *	2001-02-08	2003-12-05	Ellipse Pharmaceuticals	Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
US6777000B2 (en)	2001-02-28	2004-08-17	Carrington Laboratories, Inc.	In-situ gel formation of pectin
US7163696B2 (en) *	2001-10-11	2007-01-16	Pfizer Inc.	Pharmaceutical formulations
US6852238B2 (en) *	2002-08-29	2005-02-08	Steller Technology Company	Layered tablet water treatment compositions and method of use
US7309444B2 (en) *	2002-08-29	2007-12-18	Stellar Technology Company	Layered tablet water treatment compositions and method of use
DK1551372T3 (en)	2002-09-20	2018-07-23	Alpharma Pharmaceuticals Llc	SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
MXPA05004338A (es) *	2002-10-22	2005-06-22	Ranbaxy Lab Ltd	Composiciones de liberacion sostenida que contienen alfuzosin.
KR20070043806A (ko) *	2004-07-29	2007-04-25	사노피-아벤티스	ｐＨ에 매우 의존적인 용해도를 가지는 활성 성분의 제어방출을 위한 약제학적 다층 정제
FR2874325B1 (fr) *	2004-08-19	2006-10-20	Sanofi Synthelabo	Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US20060062845A1 (en) *	2004-09-17	2006-03-23	Cimex Pharma Ag	Alfuzosin tablets and synthesis
US20060062846A1 (en) *	2004-09-17	2006-03-23	Cimex Pharma Ag	Alfuzosin tablets and synthesis
ITMI20050391A1 (it) *	2005-03-11	2006-09-12	Ph & T S P A	Formulazioni a rilascio controllato di alfuzosin
CA2789262C (en)	2005-04-28	2016-10-04	Proteus Digital Health, Inc.	Pharma-informatics system
US8802183B2 (en)	2005-04-28	2014-08-12	Proteus Digital Health, Inc.	Communication system with enhanced partial power source and method of manufacturing same
US8836513B2 (en)	2006-04-28	2014-09-16	Proteus Digital Health, Inc.	Communication system incorporated in an ingestible product
US8912908B2 (en)	2005-04-28	2014-12-16	Proteus Digital Health, Inc.	Communication system with remote activation
US9198608B2 (en)	2005-04-28	2015-12-01	Proteus Digital Health, Inc.	Communication system incorporated in a container
JP5296531B2 (ja)	2005-05-05	2013-09-25	センシエントフレイバーズエルエルシー	βグルカン及びマンナンの製造
US20070185233A1 (en) *	2005-11-09	2007-08-09	Jayanth Rajaiah	Denture adhesive articles
US20070185237A1 (en) *	2005-11-09	2007-08-09	Jayanth Rajaiah	Denture adhesive articles
US7834066B2 (en) *	2005-11-09	2010-11-16	The Procter & Gamble Company	Denture adhesive articles
US20070185232A1 (en) *	2005-11-09	2007-08-09	Jayanth Rajaiah	Denture adhesive articles
US20070185235A1 (en) *	2005-11-09	2007-08-09	Jayanth Rajaiah	Denture adhesive compositions
US20090239972A1 (en) *	2005-11-09	2009-09-24	Jayanth Rajaiah	Denture Adhesive Compositions and Methods
US20090238776A1 (en) *	2005-11-09	2009-09-24	Arif Ali Baig	Oral Care Compositions and Methods
US20070185236A1 (en) *	2005-11-09	2007-08-09	Jayanth Rajaiah	Denture adhesive compositions
US20070129460A1 (en) *	2005-11-09	2007-06-07	Jayanth Rajaiah	Denture adhesive articles
WO2007080509A2 (en) *	2006-01-12	2007-07-19	Wockhardt Ltd	Sustained release compositions of alfuzosin
CN101496042A (zh)	2006-05-02	2009-07-29	普罗秋斯生物医学公司	患者定制的治疗方案
EP2526932B1 (en)	2006-06-19	2017-06-07	Alpharma Pharmaceuticals LLC	Pharmaceutical composition
US20080003286A1 (en) *	2006-06-29	2008-01-03	Sathya Narayana Vemula	Sustained delivery alfuzosin compositions
EP2067475A4 (en)	2006-09-26	2010-12-15	Astellas Pharma Inc	PREPARATION FOR TACROLIMUS MAINTAINED RELEASE
US20080095844A1 (en) *	2006-10-23	2008-04-24	Rajhans Sujay Kamalakar	Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
KR101611240B1 (ko)	2006-10-25	2016-04-11	프로테우스 디지털 헬스, 인코포레이티드	복용 가능한 제어된 활성화 식별자
EP2069004A4 (en)	2006-11-20	2014-07-09	Proteus Digital Health Inc	PERSONAL HEALTH SIGNAL RECEIVERS WITH ACTIVE SIGNAL PROCESSING
US20080138412A1 (en) *	2006-12-06	2008-06-12	Fu-Yung Lin	Sustained release alfuzosin hydrochl formulation and method for their production
US20100092556A1 (en) *	2006-12-11	2010-04-15	Kristin Arnold	Alfuzosin formulations, methods of making, and methods of use
US20080160081A1 (en) *	2006-12-11	2008-07-03	Mutual Pharmaceutical Company, Inc.	Alfuzosin formulations, methods of making, and methods of use
WO2008084698A1 (ja)	2006-12-28	2008-07-17	Astellas Pharma Inc.	タクロリムス徐放性医薬組成物
US8858432B2 (en)	2007-02-01	2014-10-14	Proteus Digital Health, Inc.	Ingestible event marker systems
MY154556A (en)	2007-02-14	2015-06-30	Proteus Digital Health Inc	In-body power source having high surface area electrode
WO2008102235A1 (en) *	2007-02-20	2008-08-28	Aurobindo Pharma Limited	Controlled release formulations of alfuzosin
US9270025B2 (en)	2007-03-09	2016-02-23	Proteus Digital Health, Inc.	In-body device having deployable antenna
WO2008112577A1 (en)	2007-03-09	2008-09-18	Proteus Biomedical, Inc.	In-body device having a multi-directional transmitter
US8540632B2 (en)	2007-05-24	2013-09-24	Proteus Digital Health, Inc.	Low profile antenna for in body device
EP4011289A1 (en)	2007-09-25	2022-06-15	Otsuka Pharmaceutical Co., Ltd.	In-body device with virtual dipole signal amplification
US8623418B2 (en)	2007-12-17	2014-01-07	Alpharma Pharmaceuticals Llc	Pharmaceutical composition
EP2268261B1 (en)	2008-03-05	2017-05-10	Proteus Digital Health, Inc.	Multi-mode communication ingestible event markers and systems, and methods of using the same
CN102159134B (zh)	2008-07-08	2015-05-27	普罗透斯数字保健公司	可摄取事件标记数据框架
WO2010019778A2 (en)	2008-08-13	2010-02-18	Proteus Biomedical, Inc.	Ingestible circuitry
US20100233259A1 (en) *	2008-12-12	2010-09-16	Pascal Grenier	Dosage form of ropinirole
KR20110103446A (ko)	2009-01-06	2011-09-20	프로테우스 바이오메디컬, 인코포레이티드	섭취-관련 바이오피드백 및 개별화된 의료 치료 방법 및 시스템
AU2010203737B2 (en)	2009-01-06	2016-09-15	Otsuka Pharmaceutical Co., Ltd.	Pharmaceutical dosages delivery system
WO2010083360A2 (en) *	2009-01-16	2010-07-22	Mutual Pharmaceutical Company, Inc.	Controlled-release formulations
GB2480965B (en)	2009-03-25	2014-10-08	Proteus Digital Health Inc	Probablistic pharmacokinetic and pharmacodynamic modeling
US8545402B2 (en)	2009-04-28	2013-10-01	Proteus Digital Health, Inc.	Highly reliable ingestible event markers and methods for using the same
US9149423B2 (en)	2009-05-12	2015-10-06	Proteus Digital Health, Inc.	Ingestible event markers comprising an ingestible component
TWI517050B (zh)	2009-11-04	2016-01-11	普羅托斯數位健康公司	供應鏈管理之系統
US8735465B2 (en)	2010-03-10	2014-05-27	The Procter & Gamble Company	Denture adhesive compositions
WO2011122524A1 (ja)	2010-03-29	2011-10-06	アステラス製薬株式会社	放出制御医薬組成物
US9884022B2 (en) *	2010-04-07	2018-02-06	Lupin Limited	Controlled release pharmaceutical compositions of tapentadol
JP6463599B2 (ja)	2010-04-07	2019-02-06	プロテウスデジタルヘルス，インコーポレイテッド	小型の摂取可能なデバイス
TWI557672B (zh)	2010-05-19	2016-11-11	波提亞斯數位康健公司	用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
JP2014504902A (ja)	2010-11-22	2014-02-27	プロテウスデジタルヘルス，インコーポレイテッド	医薬品を有する摂取可能なデバイス
CN102475690B (zh) *	2010-11-30	2016-06-01	安国药品株式会社	内含盐酸阿夫唑嗪的缓释片剂
WO2015112603A1 (en)	2014-01-21	2015-07-30	Proteus Digital Health, Inc.	Masticable ingestible product and communication system therefor
US9756874B2 (en)	2011-07-11	2017-09-12	Proteus Digital Health, Inc.	Masticable ingestible product and communication system therefor
IN2014MN00183A (cs)	2011-07-21	2015-06-19	Proteus Digital Health Inc
US9235683B2 (en)	2011-11-09	2016-01-12	Proteus Digital Health, Inc.	Apparatus, system, and method for managing adherence to a regimen
AU2013293234B2 (en)	2012-07-23	2017-08-31	Otsuka Pharmaceutical Co., Ltd.	Techniques for manufacturing ingestible event markers comprising an ingestible component
US9268909B2 (en)	2012-10-18	2016-02-23	Proteus Digital Health, Inc.	Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
TWI659994B (zh) *	2013-01-29	2019-05-21	美商普羅托斯數位健康公司	高度可膨脹之聚合型薄膜及包含彼之組成物
JP5941240B2 (ja)	2013-03-15	2016-06-29	プロテウスデジタルヘルス，インコーポレイテッド	金属検出器装置、システム、および方法
WO2014197402A1 (en)	2013-06-04	2014-12-11	Proteus Digital Health, Inc.	System, apparatus and methods for data collection and assessing outcomes
US9796576B2 (en)	2013-08-30	2017-10-24	Proteus Digital Health, Inc.	Container with electronically controlled interlock
US10084880B2 (en)	2013-11-04	2018-09-25	Proteus Digital Health, Inc.	Social media networking based on physiologic information
US11051543B2 (en)	2015-07-21	2021-07-06	Otsuka Pharmaceutical Co. Ltd.	Alginate on adhesive bilayer laminate film
WO2017078557A1 (ru) *	2015-11-05	2017-05-11	Анатолий Викторович ЗАЗУЛЯ	Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой аналога
EP3487393A4 (en)	2016-07-22	2020-01-15	Proteus Digital Health, Inc.	ELECTROMAGNETIC CAPTURE AND DETECTION OF INGERABLE EVENT MARKERS
KR102426632B1 (ko)	2016-10-26	2022-07-29	오오쯔까세이야꾸가부시끼가이샤	섭취 가능한 이벤트 마커를 갖는 캡슐을 제조하는 방법
CN114209668B (zh) *	2022-01-13	2023-01-31	山东新时代药业有限公司	一种盐酸阿夫唑嗪缓释制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2582513B1 (fr) *	1985-05-28	1988-08-05	Synthelabo	Compositions pharmaceutiques contenant de l'alfuzosine
IT1188212B (it) *	1985-12-20	1988-01-07	Paolo Colombo	Sistema per il rilascio a velocita' controllata di sostanze attive
IT1237904B (it) *	1989-12-14	1993-06-18	Ubaldo Conte	Compresse a rilascio a velocita' controllata delle sostanze attive
GB9311191D0 (en) *	1993-05-29	1993-07-14	Danbiosyst Uk	Controlled release drug formulation
FR2717388B1 (fr) *	1994-03-21	1996-11-22	Synthelabo	Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.

1997
- 1997-08-22 CZ CZ1999655A patent/CZ295066B6/cs not_active IP Right Cessation
- 1997-08-22 TR TR1999/00289T patent/TR199900289T2/xx unknown
- 1997-08-22 UA UA99020755A patent/UA69374C2/uk unknown
- 1997-08-22 DE DE69704712T patent/DE69704712T2/de not_active Expired - Lifetime
- 1997-08-22 PL PL331862A patent/PL191546B1/pl unknown
- 1997-08-22 RU RU99105730/14A patent/RU2183459C2/ru active
- 1997-08-22 AP APAP/P/1999/001470A patent/AP1107A/en active
- 1997-08-22 EP EP97937651A patent/EP0938318B1/fr not_active Expired - Lifetime
- 1997-08-22 KR KR1019997001666A patent/KR100364328B1/ko not_active IP Right Cessation
- 1997-08-22 US US09/147,581 patent/US6149940A/en not_active Expired - Lifetime
- 1997-08-22 CN CNB2004100422955A patent/CN100335057C/zh not_active Expired - Lifetime
- 1997-08-22 MX MXPA99001958A patent/MXPA99001958A/es active IP Right Grant
- 1997-08-22 AU AU40201/97A patent/AU724490B2/en not_active Expired
- 1997-08-22 IL IL12814697A patent/IL128146A/xx not_active IP Right Cessation
- 1997-08-22 CN CNB971975582A patent/CN1155382C/zh not_active Expired - Lifetime
- 1997-08-22 ES ES97937651T patent/ES2159400T3/es not_active Expired - Lifetime
- 1997-08-22 SK SK270-99A patent/SK284388B6/sk not_active IP Right Cessation
- 1997-08-22 HU HU9903428A patent/HU228007B1/hu unknown
- 1997-08-22 AT AT97937651T patent/ATE200864T1/de active
- 1997-08-22 NZ NZ334018A patent/NZ334018A/xx not_active IP Right Cessation
- 1997-08-22 BR BRPI9713237-3A patent/BR9713237B1/pt not_active IP Right Cessation
- 1997-08-22 EE EEP199900090A patent/EE03855B1/xx unknown
- 1997-08-22 SI SI9730158T patent/SI0938318T1/xx unknown
- 1997-08-22 PT PT97937651T patent/PT938318E/pt unknown
- 1997-08-22 DK DK97937651T patent/DK0938318T3/da active
- 1997-08-22 JP JP51133198A patent/JP3797388B2/ja not_active Expired - Lifetime
- 1997-08-22 WO PCT/FR1997/001515 patent/WO1998008515A1/fr active IP Right Grant
- 1997-08-22 CA CA002264250A patent/CA2264250C/en not_active Expired - Lifetime
- 1997-08-25 AR ARP970103839A patent/AR009312A1/es active IP Right Grant
- 1997-08-26 TW TW086112274A patent/TW522023B/zh not_active IP Right Cessation
- 1997-08-28 CO CO97049830A patent/CO4920217A1/es unknown
1999
- 1999-01-29 IS IS4964A patent/IS2091B/is unknown
- 1999-02-01 BG BG103138A patent/BG63768B1/bg unknown
- 1999-02-26 OA OA9900042A patent/OA10983A/fr unknown
- 1999-02-26 NO NO19990944A patent/NO326206B1/no not_active IP Right Cessation
- 1999-12-20 HK HK99105968A patent/HK1020875A1/xx not_active IP Right Cessation
2001
- 2001-07-26 GR GR20010401141T patent/GR3036291T3/el unknown
2002
- 2002-05-15 CY CY0200038A patent/CY2284B1/xx unknown

Also Published As

Publication number	Publication date
CY2284B1 (en)	2003-07-04
CO4920217A1 (es)	2000-05-29
PL191546B1 (pl)	2006-06-30
CZ65599A3 (cs)	1999-06-16
HUP9903428A2 (hu)	2000-02-28
HU228007B1 (en)	2012-08-28
UA69374C2 (uk)	2004-09-15
EE9900090A (et)	1999-10-15
US6149940A (en)	2000-11-21
SK284388B6 (sk)	2005-02-04
JP3797388B2 (ja)	2006-07-19
PL331862A1 (en)	1999-08-16
AP9901470A0 (en)	1999-03-31
CN1155382C (zh)	2004-06-30
DK0938318T3 (da)	2001-08-20
PT938318E (pt)	2001-10-30
RU2183459C2 (ru)	2002-06-20
IS2091B (is)	2006-03-15
EP0938318B1 (fr)	2001-05-02
WO1998008515A1 (fr)	1998-03-05
NO990944L (no)	1999-04-27
CZ295066B6 (cs)	2005-05-18
SI0938318T1 (en)	2001-12-31
KR20000035929A (ko)	2000-06-26
NO990944D0 (no)	1999-02-26
BR9713237A (pt)	2000-04-04
AU4020197A (en)	1998-03-19
TW522023B (en)	2003-03-01
IS4964A (is)	1999-01-29
CN1228700A (zh)	1999-09-15
OA10983A (fr)	2003-03-04
CA2264250A1 (en)	1998-03-05
HK1020875A1 (en)	2000-05-26
SK27099A3 (en)	1999-12-10
IL128146A0 (en)	1999-11-30
TR199900289T2 (xx)	2000-12-21
NZ334018A (en)	1999-06-29
CA2264250C (en)	2005-07-05
BG103138A (en)	1999-09-30
BG63768B1 (bg)	2002-12-29
AR009312A1 (es)	2000-04-12
CN100335057C (zh)	2007-09-05
ATE200864T1 (de)	2001-05-15
CN1543954A (zh)	2004-11-10
BR9713237B1 (pt)	2009-01-13
MXPA99001958A (es)	2005-09-08
DE69704712T2 (de)	2001-11-29
EP0938318A1 (fr)	1999-09-01
GR3036291T3 (en)	2001-10-31
AU724490B2 (en)	2000-09-21
JP2000514462A (ja)	2000-10-31
AP1107A (en)	2002-09-20
HUP9903428A3 (en)	2000-04-28
ES2159400T3 (es)	2001-10-01
IL128146A (en)	2001-01-11
DE69704712D1 (de)	2001-06-07
KR100364328B1 (ko)	2002-12-26
EE03855B1 (et)	2002-10-15

Legal Events

Date	Code	Title	Description
2017-09-11	MK1K	Patent expired

Publication	Publication Date	Title
NO326206B1 (no)	2008-10-20	Farmasoytisk tablett med kontrollert frigivelse av alfuzosinhydroklorid
TWI324075B (en)	2010-05-01	Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
KR100618234B1 (ko)	2006-09-01	다공성 입자를 포함하는 제형
AU719170B2 (en)	2000-05-04	Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids
KR20160070839A (ko)	2016-06-20	즉시 방출 남용 저지 입상 투여 형태
PL202689B1 (pl)	2009-07-31	Tabletka wielowarstwowa o kontrolowanym uwalnianiu zawierająca ropinirol i zastosowanie ropinirolu
JPH02229110A (ja)	1990-09-11	ヒドロゲルを用いた徐放製剤
JP2008510000A (ja)	2008-04-03	制御放出性ナノ粒子有効薬剤配合物投与剤型品および方法
KR20120065328A (ko)	2012-06-20	１-［２-（２,４-디메틸-페닐술파닐）-페닐］피페라진의 신규한 조성물
JP2008508270A (ja)	2008-03-21	生理活性剤の放出速度調整のために圧縮された組成物のデリバリー系
JPWO2008084698A1 (ja)	2010-04-30	タクロリムス徐放性医薬組成物
US20020119192A1 (en)	2002-08-29	Controlled release formulations for oral administration
CN103813787A (zh)	2014-05-21	可溶胀的芯/壳型药片
KR20180114515A (ko)	2018-10-18	다공성 위체류층을 포함하는 서방성 제제 및 이의 제조방법
WO2008155620A1 (en)	2008-12-24	Dosage form containing dispersible matrix of sustained release granules
CN100536838C (zh)	2009-09-09	一种盐酸坦洛新控释片制剂及其制备方法
CN101167701A (zh)	2008-04-30	盐酸坦洛新双层渗透泵控释片及其制备方法
WO2003080057A1 (fr)	2003-10-02	Comprime-noyau de taille reduite contenant de la nifedipine
Panchal et al.	0	FORMULATION EVALUATION AND OPTIMIZATION OF NOVEL TABLET FOR COMBINATION THERAPY
TH34883B (th)	2013-01-25	ยาเม็ดที่มีการควบคุมการปลดปล่อย แอลฟูโซซิน ไฮโดรคลอไรด์
TH35423A (th)	1999-10-22	ยาเม็ดที่มีการควบคุมการปลดปล่อย แอลฟูโซซิน ไฮโดรคลอไรด์